Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTC004 plus Regorafenib in Metastatic Colorectal Cancer
NCT06322563Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of LTC004 in metastatic colorectal cancer (mCRC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
LTC004
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06322563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06322563.